Nyrada

Nyrada Inc (ASX:NYR) sees its shares rise as the company’s **Xolatryp** program moves forward. The development aims to advance toward an **Investigational New Drug (IND) filing**, a critical step for clinical trials. Investors react to potential progress in the pipeline, though no formal updates on milestones or timelines are confirmed.

Nov 2026KalkineNews article

Nyrada Inc. secures a 20-year US patent for its TRPC ion channel inhibitor **Xolatryp®**, covering its chemical structure. The patent, filed in September 2024, strengthens the clinical-stage biotech’s intellectual property protections for the compound. The company specializes in developing ion channel inhibitors for potential therapeutic applications.

Sep 2026KalkineNews article

Nyrada enrolls the first patient in its **Xolatryp** clinical trial, a program evaluating a potential treatment for heart attack patients. The trial marks a key step in assessing the therapy’s safety and efficacy in reducing cardiac damage. Nyrada develops cardiovascular therapies targeting acute myocardial infarction outcomes.

Aug 2026KalkineNews article

Nyrada demonstrates **Xolatryp’s** preclinical efficacy in liver cancer, showing a **~39% improvement in response** compared to doxorubicin alone. The company also secures a **US patent allowance**, reinforcing its intellectual property position in oncology treatments.

May 2026Small CapsNews article